Establishment of a New Renal Cell Carcinoma Cell Line and a New Experimental Renal Tumor Model

Case ID:

This technology is a tumor cell line from a primary papillary renal cell carcinoma that, when implanted in the kidney of nude mice, provides a xenograft tumor model of human renal cell carcinoma.


Background & Unmet Need:

Renal cell carcinoma, which occurs in the parenchyma of the kidney, is the most common type of renal cancer, accounting for approximately 3% of adult malignancies.  Carcinoma of the renal pelvis is rare, comprising only 5% of all kidney tumors.  Renal cell carcinoma is more common in males than females and is rare in people under age 35.  Cigarette smoking is the most definitive risk factor for the development of renal cell carcinoma, with approximately 25-30% of cases directly attributable to smoking.  Renal cell carcinoma spreads locally to the medullary portion of the kidney, to the renal vein, and sometimes into the vena cava.  The most common sites of distant metastasis are the lungs, bones, brain, and liver.  Approximately 30% of patients with kidney cancer present with metastasis at diagnosis.  The kidney tumor model in mice can be used to develop new renal carcinoma drugs and to understand the different stages of tumor development.


Technology Description:

Our researcher has established a tumor cell line KCI-18 RCC from a primary renal tumor specimen obtained from a patient with papillary renal cell carcinoma (RCC) (nuclear grade III/1V).  The papillary renal carcinoma human tumor was then implanted into nude mice.  The tumor model is highly reproducible, reliable and predictable and has well‑defined kinetics.  Stability of chromosomal abnormalities has been shown following passage in kidney.  The model has shown rapid development of kidney tumors leading to animal death within 30-45 days.  This is a good model for obtaining rapid results for drug testing.


Commercial Applications:

Kidney tumor model in mice can be used to:

  • Study new drugs for the treatment of renal cell carcinoma
  • Study mechanisms of tumor development, progression, and metastasis


Stage of Development:

Preclinical; animal studies performed


Competitive Advantages:

  • Nude mouse model will not reject human transplant due to immunodeficiency status, allowing in vivo study of human tumors
  • Tumor model is highly reproducible, reliable, and predictable, with well-defined kinetics


Intellectual Property Status:

No patent information available


Related Publications or Citations of Work:


Patent Information:
For Information, Contact:
Joan Dunbar
Associate Vice President for Technology Commercialization
Wayne State University
(313) 577-5542
Gilda Hillman
Animal Model
Research Tool